Skip to main content

Advertisement

SpringerLink
Log in

Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

In East Asia, the tumor infiltrative pattern (INF) has been routinely evaluated by hematoxylin and eosin-stained sections as a pathologic characteristic of surgically resected specimens.

Methods

The infiltrative pattern of gastric cancer (GC) has been histopathologically classified as INFa (expansive growth), INFb (intermediate type) and INFc (infiltrative growth) according to the Japanese Classification of Gastric Carcinoma. The prognostic value and characteristics of the disease recurrence pattern for each INF type were assessed in 785 patients with various stages of GC and also in 243 patients with stages 2 and 3 GC.

Results

Comparison of the overall survival experienced by patients independently of stage showed that INF was significantly associated with prognosis. Specifically, peritoneal metastasis was present in 91 % of stage 4 patients in the INFc group, whereas hepatic metastasis was present in 39 % of stage 4 patients in the INFa and INFb group. After curative gastrectomy of patients with stages 2 or 3 GC, INF was not significantly associated with survival. The prevalence of peritoneal recurrence was significantly higher in the INFc group than in the INFa and INFb group, whereas the prevalence of hepatic recurrence was significantly higher in the INFa and INFb group than in the INFc group. Multivariate analysis identified INFc as an independent risk factor for peritoneal recurrence after curative gastrectomy. The association of the INF type with the incidence of peritoneal recurrence was observed with all disease stages regardless whether the patient was given adjuvant chemotherapy or not.

Conclusions

Evaluation of the INF type shows promise for its role as a predictor of postoperative recurrence sites in patients with GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015:1–12.

  3. Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.

    Article  PubMed  Google Scholar 

  4. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–90.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.

    Article  CAS  PubMed  Google Scholar 

  6. Kanda M, Kobayashi D, Tanaka C, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer. 2016;19:255–63.

    Article  CAS  PubMed  Google Scholar 

  7. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  PubMed  Google Scholar 

  8. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

    Article  CAS  PubMed  Google Scholar 

  9. Kanda M, Nomoto S, Oya H, et al. The expression of melanoma-associated antigen D2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression. Ann Surg Oncol. 2016;23:214–21.

    Article  PubMed  Google Scholar 

  10. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27–39.

    PubMed  PubMed Central  Google Scholar 

  11. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.

    Article  PubMed  Google Scholar 

  12. Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721–30.

    Article  CAS  PubMed  Google Scholar 

  13. Aoyama T, Yoshikawa T, Hayashi T, et al. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol. 2012;19:1568–74.

    Article  PubMed  Google Scholar 

  14. Kodera Y, Ito S, Mochizuki Y, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15:335–7.

    Article  PubMed  Google Scholar 

  15. Japanese Classification of Gastric Carcinoma: 3rd English ed. Gastric Cancer. 2011;14:101–12.

    Article  Google Scholar 

  16. Maehara Y, Oshiro T, Adachi Y, Ohno S, Akazawa K, Sugimachi K. Growth pattern and prognosis of gastric cancer invading the subserosa. J Surg Oncol. 1994;55:203–8.

    Article  CAS  PubMed  Google Scholar 

  17. Nishida T, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G. Histologic grade and cellular proliferation at the deepest invasive portion correlate with the high malignancy of submucosal invasive gastric carcinoma. Oncology. 1995;52:340–6.

    Article  CAS  PubMed  Google Scholar 

  18. Saito H, Miyatani K, Takaya S, et al. Tumor infiltration pattern into the surrounding tissue has prognostic significance in advanced gastric cancer. Virchows Arch. 2015;467:519–23.

    Article  CAS  PubMed  Google Scholar 

  19. Sobin LH, Gospodarowicz MK, C W. International Union Against Cancer, TNM Classification of Malignant Tumors. 7th ed. Wiley-Blackwell, New York, 2009.

  20. Song KY, Hur H, Jung CK, et al. Impact of tumor infiltration pattern into the surrounding tissue on prognosis of the subserosal gastric cancer (pT2b). Eur J Surg Oncol. 2010;36:563–7.

    Article  CAS  PubMed  Google Scholar 

  21. Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non–serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database. BMC Cancer. 2013;13:57.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kanda M, Nomoto S, Oya H, et al. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res. 2014;33:66.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.

    Article  PubMed  Google Scholar 

  24. Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.

    Article  PubMed  Google Scholar 

  25. Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.

    Article  CAS  PubMed  Google Scholar 

  26. Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015;21:9838–52.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan

    Mitsuro Kanda MD, PhD, FACS, Akira Mizuno MD, Tsutomu Fujii MD, PhD, FACS, Suguru Yamada MD, PhD, FACS, Chie Tanaka MD, PhD, Daisuke Kobayashi MD, PhD, Masahiko Koike MD, PhD, Naoki Iwata MD, PhD, Yukiko Niwa MD, PhD, Masamichi Hayashi MD, PhD, Hideki Takami MD, PhD, Goro Nakayama MD, PhD, Hiroyuki Sugimoto MD, PhD, Michitaka Fujiwara MD, PhD & Yasuhiro Kodera MD, PhD, FACS

  2. Department of Pathology, Nagoya University Hospital, Nagoya, Japan

    Yoshie Shimoyama MD, PhD

Authors
  1. Mitsuro Kanda MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Mizuno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsutomu Fujii MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshie Shimoyama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suguru Yamada MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chie Tanaka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daisuke Kobayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiko Koike MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoki Iwata MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yukiko Niwa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masamichi Hayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hideki Takami MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Goro Nakayama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroyuki Sugimoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Michitaka Fujiwara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yasuhiro Kodera MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuro Kanda MD, PhD, FACS.

Ethics declarations

Conflicts of interest

There are no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 1675 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanda, M., Mizuno, A., Fujii, T. et al. Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. Ann Surg Oncol 23, 1934–1940 (2016). https://doi.org/10.1245/s10434-016-5102-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5102-x

Keywords

Search

Navigation